Arrayit reported fulfillment of a clinical instrumentation contract with the United States Food and Drug Administration (FDA), which involves an exacting series of contractual steps including receiving the solicitation, placing the bid, winning the award, receiving the purchase order, shipping the system, gaining an installation and acceptance notice, and reporting FDA approval of payment for fulfillment of the contract. The clinical instrumentation in the FDA contract is the same technology deployed by Arrayit in its Clinical Laboratory Improvement Amendments (CLIA) laboratory licensed by the Centers for Medicare and Medicaid Services (CMS) and the State of California Department of Public Health (CDPH) for allergy and dietary wellness testing and pipeline tests for ovarian cancer and Parkinson’s Disease (PD). Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the FDA regarding approval of a major product line, signed allergy testing contracts with more than 300 medical clinics, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing by CMS, launched the Patient Data Solutions allergy portal for doctors and clinics, celebrated 25 years of company operations, and announced an allergy testing services agreement with a major health and wellness provider. Fulfilling the FDA clinical instrumentation contract strengthens the company’s relationship with the agency that ensures the safety of medical devices and pharmaceutical consumer healthcare products exceeding $1,000,000,000,000 in annual revenues.